Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Halford

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Frontiers in Oncology|March 20, 2023
Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspectiveRavindhi Murphy, Sarah Halford, Stefan Nicholas Symeonides
Current Medical Research and Opinion|January 28, 2026
Improving preclinical and clinical oncology research through patient integrationSteve Clark, Rachel Grimley, Sarah Halford, et al.
The Journal of Pathology|June 26, 2002
Does MSI-low exist?Ian Tomlinson, Sarah Halford, Lauri Aaltonen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2016
Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experienceHan Hsi Wong, Claire Barton, Gary Acton, et al.
Statistics in Medicine|April 13, 2012
A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancerJohn Whitehead, Helene Thygesen, Thomas Jaki, et al.
Cancer Research|January 10, 2002
Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative traitSarah Halford, Peter Sasieni, Andrew Rowan, et al.
Trials|August 20, 2021
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusionSarah Halford, Susan Wan, Ilaria Dragoni, et al.
Cancer Research|July 17, 2004
Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomasEleanor J Douglas, Heike Fiegler, Andrew Rowan, et al.
Cancer Research|December 17, 2005
CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instabilityZoe Kemp, Andrew Rowan, William Chambers, et al.
British Journal of Cancer|March 24, 2020
Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965Rosie McNeillis, Alastair Greystoke, Jon Walton, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|March 20, 2023
Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspectiveRavindhi Murphy, Sarah Halford, Stefan Nicholas Symeonides
Current Medical Research and Opinion|January 28, 2026
Improving preclinical and clinical oncology research through patient integrationSteve Clark, Rachel Grimley, Sarah Halford, et al.
The Journal of Pathology|June 26, 2002
Does MSI-low exist?Ian Tomlinson, Sarah Halford, Lauri Aaltonen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2016
Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experienceHan Hsi Wong, Claire Barton, Gary Acton, et al.
Statistics in Medicine|April 13, 2012
A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancerJohn Whitehead, Helene Thygesen, Thomas Jaki, et al.
Cancer Research|January 10, 2002
Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative traitSarah Halford, Peter Sasieni, Andrew Rowan, et al.
Trials|August 20, 2021
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusionSarah Halford, Susan Wan, Ilaria Dragoni, et al.
Cancer Research|July 17, 2004
Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomasEleanor J Douglas, Heike Fiegler, Andrew Rowan, et al.
Cancer Research|December 17, 2005
CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instabilityZoe Kemp, Andrew Rowan, William Chambers, et al.
British Journal of Cancer|March 24, 2020
Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965Rosie McNeillis, Alastair Greystoke, Jon Walton, et al.
Pageof 3